The Drugs Controller General of India (DGCI) has approved Sanofi and GlaxoSmithKline to conduct Phase III studies to assess the safety, efficacy and immunogenicity of their anti-COVID-19 vaccines in India. The double-blind phase-III study will involve over 35,000 volunteers aged 18 years. The main objective of the test is to prevent COVID-19 infection as well as reduce severe disease symptoms. The initial study will examine the efficacy of a vaccine formulation targeting the virus strain (D614), while the second phase will evaluate a second formulation targeting the beta variant (B1351). The Phase II trial involved 722 adults aged between 18 and 95.